V-Square Quantitative Management’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.04M Buy
52,713
+4,478
+9% +$257K 0.29% 46
2026
Q1
$2.93M Buy
48,235
+1,841
+4% +$107K 0.31% 48
2025
Q4
$2.5M Sell
46,394
-4,969
-10% -$239K 0.26% 58
2025
Q3
$2.32M Buy
51,363
+2,535
+5% +$118K 0.39% 49
2025
Q2
$2.26M Buy
48,828
+2,429
+5% +$119K 0.3% 58
2025
Q1
$2.83M Buy
46,399
+1,305
+3% +$76.1K 0.41% 43
2024
Q4
$2.55M Buy
45,094
+1,462
+3% +$81.7K 0.36% 45
2024
Q3
$2.26M Buy
43,632
+1,580
+4% +$74.1K 0.33% 51
2024
Q2
$1.75M Sell
42,052
-193
-0.5% -$8.64K 0.28% 57
2024
Q1
$2.29M Buy
42,245
+8,211
+24% +$418K 0.32% 45
2023
Q4
$1.75M Buy
34,034
+17,016
+100% +$893K 0.31% 42
2023
Q3
$988K Buy
17,018
+4,140
+32% +$254K 0.43% 33
2023
Q2
$824K Sell
12,878
-5,320
-29% -$357K 0.6% 31
2023
Q1
$1.26M Buy
+18,198
New +$1.28M 1.16% 21

Other funds holding BMY

V-Square Quantitative Management's BMY Position: Q2 2026 in Review

V-Square Quantitative Management increased its Bristol-Myers Squibb (BMY) stake by 9.3% in Q2 2026, buying an estimated $257K and bringing the position to 52,713 shares worth $3.04M. The position accounts for 0.29% of the portfolio, ranked #46.

V-Square Quantitative Management first reported a position in BMY in Q1 2023 and has held it in 14 quarters since. 878 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • V-Square Quantitative Management held 52,713 shares of Bristol-Myers Squibb worth $3.04M as of Q2 2026.
  • V-Square Quantitative Management bought 4,478 Bristol-Myers Squibb shares in Q2 2026, an estimated $257K.
  • Bristol-Myers Squibb made up 0.29% of V-Square Quantitative Management's portfolio in Q2 2026, its #46 holding.
  • V-Square Quantitative Management first reported a position in Bristol-Myers Squibb in Q1 2023 and has held it in 14 quarters since.
  • 878 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on V-Square Quantitative Management's 13F filing for Q2 2026, filed 27 Jul 2026.